PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
5.95%
Growth of 5.95% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
5.09%
Cost growth of 5.09% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
9.53%
Growth of 9.53% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
3.38%
Margin change of 3.38% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
-8.04%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
3.54%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 0.92%. Jim Chanos would check for waste.
4.84%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 0.07%. Jim Chanos would check for waste.
-3.85%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-8.08%
D&A reduction while Medical - Pharmaceuticals median is 1.01%. Seth Klarman would investigate efficiency.
28.62%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
21.40%
Margin change of 21.40% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
30.10%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
22.79%
Margin change of 22.79% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
918.67%
Other expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 27.02%. Jim Chanos would check for issues.
43.91%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
35.83%
Margin change of 35.83% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
45.93%
Tax expense growth exceeding 1.5x Medical - Pharmaceuticals median of 11.52%. Jim Chanos would check for issues.
42.72%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
34.70%
Margin change of 34.70% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
42.72%
EPS change of 42.72% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
42.72%
Diluted EPS change of 42.72% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.07%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.